Does a high nuclear basal level of ERK2 phosphorylation contribute to the resistance of cisplatin-resistant human ovarian cancer cells?
These results collectively indicate that prelocalization of activated ERK2 in the nuclei contribute to cisplatin resistance in OVCAR-3/CDDP cells.
Based on these results, immunohistochemical microvessel count seemed to decrease as colorectal cancer progressed and was not a reliable prognostic predictor in colorectal carcinoma.